Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations

OBJECTIVE: To analyze anti-SARS-CoV-2-S1-IgG levels, avidity, Omicron BA.2 variant neutralizing capacity, and SARS-CoV-2-specific T cells in anti-CD20-treated patients with multiple sclerosis (aCD20pwMS) after two, three, or four COVID-19 vaccinations. RESULTS: Frequencies of aCD20pwMS with detectab...

Descripción completa

Detalles Bibliográficos
Autores principales: Otto, Carolin, Schwarz, Tatjana, Jeworowski, Lara M, Schmidt, Marie L, Walper, Felix, Pache, Florence, Schindler, Patrick, Niederschweiberer, Moritz, Krumbholz, Andi, Rose, Ruben, Drosten, Christian, Ruprecht, Klemens, Corman, Victor M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051002/
https://www.ncbi.nlm.nih.gov/pubmed/36974938
http://dx.doi.org/10.1177/13524585231161253
_version_ 1785014759735689216
author Otto, Carolin
Schwarz, Tatjana
Jeworowski, Lara M
Schmidt, Marie L
Walper, Felix
Pache, Florence
Schindler, Patrick
Niederschweiberer, Moritz
Krumbholz, Andi
Rose, Ruben
Drosten, Christian
Ruprecht, Klemens
Corman, Victor M
author_facet Otto, Carolin
Schwarz, Tatjana
Jeworowski, Lara M
Schmidt, Marie L
Walper, Felix
Pache, Florence
Schindler, Patrick
Niederschweiberer, Moritz
Krumbholz, Andi
Rose, Ruben
Drosten, Christian
Ruprecht, Klemens
Corman, Victor M
author_sort Otto, Carolin
collection PubMed
description OBJECTIVE: To analyze anti-SARS-CoV-2-S1-IgG levels, avidity, Omicron BA.2 variant neutralizing capacity, and SARS-CoV-2-specific T cells in anti-CD20-treated patients with multiple sclerosis (aCD20pwMS) after two, three, or four COVID-19 vaccinations. RESULTS: Frequencies of aCD20pwMS with detectable SARS-CoV-2-S1-IgG increased moderately between two (31/61 (51%)), three (31/57 (54%)), and four (17/26 (65%)) vaccinations. However, among patients with detectable SARS-CoV-2-S1-IgG, frequencies of high avidity (6/31 (19%) vs 11/17 (65%)) and Omicron neutralizing antibodies (0/10 (0%) vs 6/10 (60%)) increased strongly between two and four vaccinations. SARS-CoV-2-specific T cells were detectable in >92% after two or more vaccinations CONCLUSION: Additional vaccinations qualitatively improve SARS-CoV-2 antibody responses.
format Online
Article
Text
id pubmed-10051002
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-100510022023-03-29 Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations Otto, Carolin Schwarz, Tatjana Jeworowski, Lara M Schmidt, Marie L Walper, Felix Pache, Florence Schindler, Patrick Niederschweiberer, Moritz Krumbholz, Andi Rose, Ruben Drosten, Christian Ruprecht, Klemens Corman, Victor M Mult Scler Short Reports OBJECTIVE: To analyze anti-SARS-CoV-2-S1-IgG levels, avidity, Omicron BA.2 variant neutralizing capacity, and SARS-CoV-2-specific T cells in anti-CD20-treated patients with multiple sclerosis (aCD20pwMS) after two, three, or four COVID-19 vaccinations. RESULTS: Frequencies of aCD20pwMS with detectable SARS-CoV-2-S1-IgG increased moderately between two (31/61 (51%)), three (31/57 (54%)), and four (17/26 (65%)) vaccinations. However, among patients with detectable SARS-CoV-2-S1-IgG, frequencies of high avidity (6/31 (19%) vs 11/17 (65%)) and Omicron neutralizing antibodies (0/10 (0%) vs 6/10 (60%)) increased strongly between two and four vaccinations. SARS-CoV-2-specific T cells were detectable in >92% after two or more vaccinations CONCLUSION: Additional vaccinations qualitatively improve SARS-CoV-2 antibody responses. SAGE Publications 2023-03-28 2023-06 /pmc/articles/PMC10051002/ /pubmed/36974938 http://dx.doi.org/10.1177/13524585231161253 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Short Reports
Otto, Carolin
Schwarz, Tatjana
Jeworowski, Lara M
Schmidt, Marie L
Walper, Felix
Pache, Florence
Schindler, Patrick
Niederschweiberer, Moritz
Krumbholz, Andi
Rose, Ruben
Drosten, Christian
Ruprecht, Klemens
Corman, Victor M
Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations
title Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations
title_full Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations
title_fullStr Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations
title_full_unstemmed Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations
title_short Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations
title_sort humoral immune responses remain quantitatively impaired but improve qualitatively in anti-cd20-treated patients with multiple sclerosis after three or four covid-19 vaccinations
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051002/
https://www.ncbi.nlm.nih.gov/pubmed/36974938
http://dx.doi.org/10.1177/13524585231161253
work_keys_str_mv AT ottocarolin humoralimmuneresponsesremainquantitativelyimpairedbutimprovequalitativelyinanticd20treatedpatientswithmultiplesclerosisafterthreeorfourcovid19vaccinations
AT schwarztatjana humoralimmuneresponsesremainquantitativelyimpairedbutimprovequalitativelyinanticd20treatedpatientswithmultiplesclerosisafterthreeorfourcovid19vaccinations
AT jeworowskilaram humoralimmuneresponsesremainquantitativelyimpairedbutimprovequalitativelyinanticd20treatedpatientswithmultiplesclerosisafterthreeorfourcovid19vaccinations
AT schmidtmariel humoralimmuneresponsesremainquantitativelyimpairedbutimprovequalitativelyinanticd20treatedpatientswithmultiplesclerosisafterthreeorfourcovid19vaccinations
AT walperfelix humoralimmuneresponsesremainquantitativelyimpairedbutimprovequalitativelyinanticd20treatedpatientswithmultiplesclerosisafterthreeorfourcovid19vaccinations
AT pacheflorence humoralimmuneresponsesremainquantitativelyimpairedbutimprovequalitativelyinanticd20treatedpatientswithmultiplesclerosisafterthreeorfourcovid19vaccinations
AT schindlerpatrick humoralimmuneresponsesremainquantitativelyimpairedbutimprovequalitativelyinanticd20treatedpatientswithmultiplesclerosisafterthreeorfourcovid19vaccinations
AT niederschweiberermoritz humoralimmuneresponsesremainquantitativelyimpairedbutimprovequalitativelyinanticd20treatedpatientswithmultiplesclerosisafterthreeorfourcovid19vaccinations
AT krumbholzandi humoralimmuneresponsesremainquantitativelyimpairedbutimprovequalitativelyinanticd20treatedpatientswithmultiplesclerosisafterthreeorfourcovid19vaccinations
AT roseruben humoralimmuneresponsesremainquantitativelyimpairedbutimprovequalitativelyinanticd20treatedpatientswithmultiplesclerosisafterthreeorfourcovid19vaccinations
AT drostenchristian humoralimmuneresponsesremainquantitativelyimpairedbutimprovequalitativelyinanticd20treatedpatientswithmultiplesclerosisafterthreeorfourcovid19vaccinations
AT ruprechtklemens humoralimmuneresponsesremainquantitativelyimpairedbutimprovequalitativelyinanticd20treatedpatientswithmultiplesclerosisafterthreeorfourcovid19vaccinations
AT cormanvictorm humoralimmuneresponsesremainquantitativelyimpairedbutimprovequalitativelyinanticd20treatedpatientswithmultiplesclerosisafterthreeorfourcovid19vaccinations

Ejemplares similares